Karsinoma Urotelial

01Pathophysiology

Urothelial carcinoma arises from the transitional epithelium (urothelium) that lines the entire urinary tract, from the renal pelvis through the ureters, bladder, and proximal urethra. The bladder is the most common site, accounting for roughly 90% of all bladder malignancies and about 90-95% of urothelial carcinomas overall.

The central mechanism is prolonged carcinogen contact with the bladder mucosa. Inhaled or ingested carcinogens are metabolized in the liver and excreted by the kidneys into the urine. Because the bladder functions as a reservoir, these carcinogens remain in direct contact with the urothelium for hours at a time. This is why smoking is the single strongest modifiable risk factor: tobacco metabolites such as 2-naphthylamine and 4-aminobiphenyl are filtered into the urine and bathe the bladder wall. Occupational carcinogens in the rubber, textile, and dye industries (aromatic amines, benzidine) follow the same excretory pathway.

Cyclophosphamide, an alkylating chemotherapeutic agent, produces the toxic metabolite acrolein, which accumulates in the bladder and causes both hemorrhagic cystitis and long-term urothelial carcinoma risk. This is the reason why mesna (2-mercaptoethane sulfonate sodium) is co-administered with cyclophosphamide: mesna binds acrolein in the urine and neutralizes it.

Urothelial carcinoma tends to grow in two distinct morphological patterns, and this is high-yield because it drives the entire treatment algorithm:

• Papillary tumors (Ta) grow outward into the bladder lumen on a stalk. These are typically low-grade and non-invasive, confined to the mucosa. They have a high recurrence rate but a low progression rate.

• Flat tumors (CIS, or Tis) grow along the surface of the urothelium without forming a visible mass. Despite being "flat" and non-invasive, CIS is high-grade by definition and carries a much higher risk of progressing to muscle-invasive disease. This is a frequently tested concept: CIS is non-invasive but biologically aggressive.

When a tumor invades into the lamina propria (T1), it remains classified as non-muscle-invasive but is considered high-risk. The pivotal distinction on the exam is whether the tumor has invaded the muscularis propria (detrusor muscle), which defines T2 disease and the transition from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). This single boundary changes the entire management from organ-preserving (TURBT + intravesical therapy) to radical surgery (cystectomy).

The reason painless hematuria is the classic presentation connects directly to the pathology: the friable, vascularized tumor surface bleeds into the urine without necessarily causing pain because the bladder wall itself has limited somatic pain innervation in the mucosal layer. When CIS is present, however, the diffuse inflammation of the urothelium triggers irritative symptoms (urgency, frequency, dysuria), which can mimic a urinary tract infection and is a common source of diagnostic delay.

02Classification and Clinical Manifestation

TNM Staging of Bladder Urothelial Carcinoma

WHO Grading System (2004/2016)

Risk Stratification for Non-Muscle-Invasive Disease

Clinical Manifestation

03Diagnostic Workup

The initial evaluation of a patient with painless hematuria should begin with a urinalysis to confirm the presence of blood and exclude infection. In patients older than 35 with unexplained hematuria (or younger patients with risk factors), the workup should proceed to imaging and cystoscopy. Do not dismiss hematuria as "likely UTI" in a patient with risk factors for malignancy; this is a common trap.

Urine cytology is an important non-invasive test. It has high sensitivity for detecting high-grade urothelial carcinoma and CIS (because high-grade cells exfoliate readily), but it has poor sensitivity for low-grade papillary tumors. A positive cytology in the setting of a normal cystoscopy should prompt investigation of the upper tract (renal pelvis, ureters), because the malignant cells may be originating from above the bladder.

CT urogram is the preferred imaging study. It evaluates the entire urinary tract in a single examination, identifying bladder masses, upper tract urothelial tumors, filling defects in the renal pelvis or ureters, and hydronephrosis. It also provides staging information about perivesical fat invasion and lymphadenopathy. This replaces the older intravenous pyelogram (IVP) in current practice.

Cystoscopy with transurethral resection of bladder tumor (TURBT) is both diagnostic and therapeutic. The urologist directly visualizes the bladder mucosa, identifies the tumor, and performs a complete resection that includes the muscularis propria (detrusor muscle) in the specimen. This last point is critical: if muscle is not present in the TURBT specimen, the pathologist cannot determine whether the tumor is muscle-invasive or not, and a repeat TURBT (re-TURBT) is required. Re-TURBT is also recommended for all T1 high-grade tumors within 2 to 6 weeks, because there is a significant rate of residual disease and understaging.

For patients with confirmed muscle-invasive disease, additional staging with chest CT and bone scan is performed to evaluate for metastatic disease before proceeding with definitive treatment.

04Management and Treatment

Non-Muscle-Invasive Bladder Cancer (NMIBC)

After TURBT, the next step depends on risk stratification. For low-risk tumors, a single instillation of intravesical chemotherapy (typically mitomycin C 40 mg or gemcitabine 2 g in saline) is administered within 24 hours of resection. This single dose reduces the recurrence rate by approximately 40%. It is contraindicated if there is suspected bladder perforation during TURBT.

For high-risk NMIBC, the cornerstone adjuvant therapy is intravesical BCG (Bacillus Calmette-Guerin). BCG is a live attenuated strain of Mycobacterium bovis that triggers a potent local immune response in the bladder wall. The induction regimen consists of weekly intravesical instillations for 6 consecutive weeks, typically initiated 2 to 4 weeks after TURBT to allow mucosal healing and reduce the risk of systemic BCG absorption. This waiting period is critical: administering BCG too soon after TURBT, during active hematuria, or after traumatic catheterization risks BCG sepsis, a life-threatening complication.Following a complete response to induction, maintenance BCG is administered using the SWOG (Southwest Oncology Group) protocol: 3 weekly instillations given at months 3, 6, 12, 18, 24, 30, and 36 after the start of induction. This remains the only maintenance regimen with proven efficacy in reducing both recurrence and progression. For intermediate-risk patients, at least 1 year of maintenance is recommended; for high-risk patients, the full 3-year course is standard.

Contraindications to intravesical BCG include: TURBT performed within the preceding 2 weeks, traumatic catheterization, gross hematuria, urethral stenosis, active tuberculosis, prior BCG sepsis, and immunosuppression. These are testable because they all relate to the same principle: BCG is a live organism, and breaching the barrier between it and the systemic circulation can produce disseminated BCG infection.

If a patient has BCG-unresponsive disease (failure to respond after adequate BCG, defined as persistent or recurrent high-grade disease after at least two courses including one induction plus maintenance), radical cystectomy is preferred. For patients with CIS who are ineligible for or elect not to undergo cystectomy, pembrolizumab is an approved option.

Muscle-Invasive Bladder Cancer (MIBC)

The standard of care for localized MIBC (T2-T4a, N0, M0) in a patient who is fit for cisplatin is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with bilateral pelvic lymph node dissection. The most commonly used regimen is gemcitabine + cisplatin (GC), administered for 3 to 4 cycles before surgery. Neoadjuvant chemotherapy provides a proven overall survival benefit (approximately 5% absolute improvement at 5 years) and is preferred over adjuvant chemotherapy because it allows drug delivery while the patient still has intact renal function (prior to the potential need for urinary diversion) and can treat micrometastatic disease early.

Radical cystectomy in men includes removal of the bladder, prostate, seminal vesicles, and distal ureters. In women, it typically includes removal of the bladder, uterus, ovaries, anterior vaginal wall, and urethra. Urinary diversion is performed, most commonly via an ileal conduit (Bricker method) or a continent neobladder (Studer or other orthotopic reconstruction).

Cisplatin eligibility is a frequently tested concept. A patient is considered ineligible for cisplatin if they have any of the following: , ECOG performance status of 2 or worse, grade 2 or higher hearing loss, grade 2 or higher peripheral neuropathy, or NYHA class III or higher heart failure. For cisplatin-ineligible patients, options include cystectomy alone or trimodal therapy (maximal TURBT + concurrent chemoradiation using radiosensitizing agents such as 5-FU + mitomycin C or gemcitabine) as a bladder-sparing alternative.

Metastatic Disease

First-line treatment for metastatic urothelial carcinoma in cisplatin-eligible patients is gemcitabine + cisplatin. For cisplatin-ineligible patients, gemcitabine + carboplatin is used, though outcomes are inferior. Following platinum-based chemotherapy, maintenance avelumab (a PD-L1 inhibitor) is recommended for patients whose disease has not progressed, based on trial data showing improved overall survival. Second-line options include pembrolizumab and erdafitinib (for tumors harboring susceptible FGFR3 alterations).

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students lose points on urothelial carcinoma questions is by failing to recognize painless hematuria as an oncologic emergency until proven otherwise. When a vignette presents an older adult (particularly a smoker) with painless gross hematuria, the reflex should be cancer workup (cystoscopy + CT urogram), not empiric antibiotics for a presumed UTI. The absence of pain is the distinguishing feature, and many students instinctively associate blood in the urine with stones or infection, both of which typically hurt.

A second common trap involves the CIS presentation. Because CIS causes irritative symptoms (dysuria, urgency, frequency) rather than visible hematuria, students often choose "UTI" or "interstitial cystitis" as the answer. The clue is that the patient's symptoms are refractory to antibiotics, urine cultures are negative, and the patient has a smoking history or other risk factors. CIS also appears as a flat, erythematous area on cystoscopy that can be mistaken for simple inflammation, so biopsy of suspicious flat lesions is essential.

A third high-yield trap involves the TURBT specimen lacking muscularis propria. If the pathology report for a T1 high-grade tumor does not contain detrusor muscle in the specimen, the tumor cannot be adequately staged. The answer in that scenario is always repeat TURBT within 2 to 6 weeks, not "start BCG" and not "proceed to cystectomy."

Students also confuse the association between Schistosoma haematobium and squamous cell carcinoma of the bladder (not urothelial carcinoma). If a vignette describes a patient from an endemic region (Egypt, sub-Saharan Africa) with chronic hematuria and bladder calcifications, the expected histology is squamous cell carcinoma, not transitional cell.

Finally, remember that cyclophosphamide causes hemorrhagic cystitis acutely (prevented by mesna) and urothelial carcinoma as a late complication. These are two distinct complications of the same drug, and the question may test either one depending on the timeline.

The core competency being tested across all these questions is pattern recognition: connecting a painless hematuria presentation with the correct risk factors, choosing the right diagnostic sequence (urinalysis, then CT urogram + cystoscopy with TURBT), correctly staging the disease by confirming whether muscle is involved, and selecting the appropriate management tier (intravesical therapy for NMIBC vs. neoadjuvant chemotherapy + cystectomy for MIBC).